MedPath

Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma

Completed
Conditions
Diffuse Large B-cell Lymphoma
Registration Number
NCT01606605
Lead Sponsor
Samsung Medical Center
Brief Summary

The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay. The investigators also study the pattern of microRNA from patients with diffuse large B-cell lymphoma. The results of gene expression profiles and microRNA is correlated with clinical outcomes of diffuse large B-cell lymphoma.

Detailed Description

1. Whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay

* Diffuse large B-cell lymphoma patients

* Paraffin-embedded tissue

* End points: Progression-free survival, overall survival

* Statistics: Leave one-out method

2. Nano string assay for microRNA

* Diffuse large B-cell lymphoma patients

* Paraffin-embedded tissue

* End points: Progression-free survival, overall survival

* Statistics: Leave one-out method

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
350
Inclusion Criteria
  • Patients diagnosed with diffuse large B-cell lymphoma
  • Patients with tissue blocks available for study
  • Patients with adequate medical records
Read More
Exclusion Criteria
  • Patients diagnosed with other subtypes of lymphoma
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of patients who relapse or progress after 1st line chemotherapytwo years
Secondary Outcome Measures
NameTimeMethod
Number and type of genes and microRNA which are significantly related with relapse or progression (P < 0.05)two years

Trial Locations

Locations (1)

Samsung Cancer Research Institute

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath